HURA (TuHURA Biosciences) ROCE %: -133.28% (As of Mar. 2026)


HURA TuHURA Biosciences Inc HURA
12 GF Score
Price $2.59
! 1 Warning Sign
View Full Analysis

What is TuHURA Biosciences ROCE %?

TuHURA Biosciences HURA +2.57% 12 ROCE % is -133.28% as of Mar. 2026. GuruFocus rates HURA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TuHURA Biosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -133.28%.

TuHURA Biosciences  (NAS:HURA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TuHURA Biosciences ROCE % Related Terms

TuHURA Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for TuHURA Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences ROCE % Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 -161.84 -447.61 -227.80 -163.16

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -217.65 -259.99 -156.11 -128.53 -133.28
HURA
12GF Score
TuHURA Biosciences Inc HURA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TuHURA Biosciences ROCE % Calculation

TuHURA Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-29.427/( ( (19.967 - 5.33) + (27.353 - 5.919) )/ 2 )
=-29.427/( (14.637+21.434)/ 2 )
=-29.427/18.0355
=-163.16 %

TuHURA Biosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-30.036/( ( (27.353 - 5.919) + (29.705 - 6.067) )/ 2 )
=-30.036/( ( 21.434 + 23.638 )/ 2 )
=-30.036/22.536
=-133.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -133.28% mean?
TuHURA Biosciences (HURA) has a ROCE % of -133.28% as of Mar. 2026.
Is TuHURA Biosciences' ROCE % too high?
TuHURA Biosciences' current ROCE % is -133.28%. Overall, TuHURA Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TuHURA Biosciences' ROCE % compare to AGEN and CRBP?
TuHURA Biosciences' ROCE % of -133.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. TuHURA Biosciences's current ROCE % is -133.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TuHURA Biosciences stock overvalued right now?
TuHURA Biosciences (HURA) has a current ROCE % of -133.28%. The current ROCE % is -133.28%. TuHURA Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TuHURA Biosciences (HURA), the current ROCE % is -133.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TuHURA Biosciences Business Description

Other Exchanges PL3:Germany
Address 10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
12GF Score

Get the complete analysis for HURA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price